B+
Bull case
25%
Probability
Target price
$60.00
Analysis reference price unavailable
Analysis 2026-09-24 · RankAlpha Sentiment Codex
LBRX
LBDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Accelerated NOVA-2 timing and a stated funding runway beyond Q2 2029 give LB-102 several potential clinical milestones without an immediately indicated financing need. The company reported $327.8 million of cash, equivalents and marketable securities at June 30, before proceeds from its recent $150 million private placement.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -4.1.
What can break
FDA feedback, enrollment timing and later mood-disorder readouts remain uncertain.
Momentum
55
Value
41
Sentiment
43
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $33.00 · Bull $60.00 · Bear $15.00Analysis 2026-09-24; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-24 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $58.92
Why
Momentum55 · Δ7d +27.9
Value41 · Δ7d -0.1
Sentiment43 · Δ7d -4.1
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -4.1.
Contradictions & invalidation
- • FDA feedback, enrollment timing and later mood-disorder readouts remain uncertain.
- • NOVA-2 efficacy or safety disappointment could materially impair the central LB-102 thesis.
- • NOVA-2 is a binary Phase 3 readout, while development spending has risen sharply: Q2 2026 R&D expense was $44.1 million versus $2.4 million a year earlier, principally driven by the schizophrenia trial.
Catalyst clock
2027-03-31
Adjunctive MDD program initiation
Lead driver: Sentiment · See AI snapshot
Momentum
55
8% active weight
Current posture
7d trendImproving
Δ7d
+27.9
Δ21d
+0.7
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.4
Sentiment
43
45% active weight
Current posture
7d trendSoftening
Δ7d
-4.1
Δ21d
-12.6
Why this grade
Composite grade D. Momentum 54.8 / Value 40.6 / Sentiment 43.2
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-24. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$33.00
Analysis reference price unavailable
Analysis 2026-09-24 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$15.00
Analysis reference price unavailable
Analysis 2026-09-24 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$1.25B
Beta
-
Shares Out
32.26M
P/E (TTM) · Derived
-38.9
P/S (TTM)
-
P/FCF (TTM) · Derived
-13.19
Rev YoY
-
EPS YoY
+689.0%
Gross Margin
-
Op Margin
-
Net Debt
-$291.64M
Current Ratio
15.08
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data